Labcorp insider trading
Every open-market purchase and sale by Labcorp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Labcorp’s insiders pay?
From April 27, 2010 to August 6, 2026, 30 insiders reported 5 open-market purchases and 117 sales not made under a pre-set plan in Labcorp. Twelve months after each purchase was reported, the shares were +1.1% against the S&P 500 on average (median −1.8%), over 5 purchases with a full year of prices; 40% beat the index. After sales, the shares moved −4.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 29, 2010 into $23,286 by November 2, 2026, +5.3% a year. It held shares 22% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $23,168 (+5.3% a year), and held throughout $91,323 (+14.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Belingard Jean-Luc | Director | 0 | — | — | 11 | −0.5% (11) | May 5, 2021 |
| Eisenberg Glenn A | Executive Vice President | 0 | — | — | 10 | −5.0% (10) | December 4, 2024 |
| Eberts F Samuel III | Chief Legal Officer, Secretary | 0 | — | — | 9 | −9.6% (9) | August 29, 2017 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 0 | — | — | 9 | −6.1% (8) | August 5, 2026 |
| Mittelstaedt Robert E Jr | Director | 0 | — | — | 8 | −1.9% (8) | February 27, 2017 |
| Van Der Vaart Sandra D | EVP, Corporate Affairs | 0 | — | — | 7 | −2.8% (6) | March 3, 2026 |
| Williams R Sanders | Director | 0 | — | — | 7 | −3.4% (7) | August 15, 2017 |
| Anderson Kerrii B | Director | 0 | — | — | 6 | −7.6% (6) | March 7, 2025 |
| Lane Wendy E | Director | 0 | — | — | 6 | −0.2% (6) | May 2, 2014 |
| Uthgenannt Lisa J | Chief Human Resources Officer | 0 | — | — | 6 | −8.1% (6) | September 6, 2019 |
| Gilliland Dwight Gary | Director | 0 | — | — | 5 | −6.3% (5) | August 1, 2025 |
| Berberian Lance | EVP, CIO & CTO | 0 | — | — | 4 | −4.3% (4) | August 7, 2024 |
| Caveney Brian J | EVP, Pres of ED, CMO & CSO | 2 | −9.0% (2) | 0% | 2 | −16.5% (1) | February 26, 2026 |
| Kirchgraber Paul R | CEO, Covance Drug Development | 0 | — | — | 4 | −12.8% (4) | May 23, 2023 |
| Boyle James T. JR. | EVP, Chief Operating Officer | 0 | — | — | 3 | −8.0% (3) | June 10, 2014 |
| Dodson Edward T | Principal Accounting Officer | 0 | — | — | 3 | −8.9% (3) | June 8, 2018 |
| Hayes William B | Chief Financial Officer, EVP | 0 | — | — | 3 | +10.1% (3) | June 10, 2014 |
| Summy Amy B. | EVP, Chief Marketing Officer | 0 | — | — | 3 | −8.5% (2) | August 6, 2026 |
| Mac Mahon Thomas P | Director | 0 | — | — | 2 | −11.4% (2) | September 10, 2012 |
| Weikel M Keith | Director | 0 | — | — | 2 | −4.2% (2) | May 9, 2014 |
| Conrad Andrew J | EVP, Chief Scientific Officer | 1 | +2.9% (1) | 100% | 0 | — | July 28, 2010 |
| Divincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | 0 | — | — | 1 | −2.0% (1) | February 22, 2024 |
| Gary M. Huff | CEO, LabCorp Diagnostics | 0 | — | — | 1 | −13.8% (1) | June 1, 2018 |
| Herring Joseph L | CEO of Covance Drug Division | 0 | — | — | 1 | −5.3% (1) | February 27, 2015 |
| King David P | Director | 0 | — | — | 1 | +20.4% (1) | May 7, 2020 |
| Neupert Peter M | Director | 1 | −1.8% (1) | 0% | 0 | — | February 18, 2022 |
| Parham Richelle P | Director | 0 | — | — | 1 | — | November 4, 2025 |
| Schechter Adam H | President & CEO | 0 | — | — | 1 | — | March 5, 2026 |
| Seltz Judith C | EVP, CHRO | 1 | +22.1% (1) | 100% | 0 | — | May 4, 2020 |
| Walton Andrew Scott | EVP | 0 | — | — | 1 | −5.6% (1) | November 2, 2010 |
When several insiders traded Labcorp
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Labcorp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 13 selling crowds, −3.2%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 3 selling | −8.3% | −1.8% | not yet |
| December 31, 2024 | 4 selling | +10.2% | +6.6% | −7.1% |
| August 30, 2024 | 3 selling | −2.0% | +7.2% | +4.5% |
| May 31, 2024 | 3 selling | +11.1% | +9.5% | +17.6% |
| June 29, 2018 | 6 selling | −10.9% | −22.7% | −13.3% |
| August 31, 2017 | 5 selling | −6.7% | −0.2% | −9.3% |
| March 31, 2017 | 3 selling | +4.4% | −2.4% | +1.2% |
| August 31, 2016 | 3 selling | −10.0% | −7.0% | −1.6% |
| May 29, 2015 | 3 selling | +6.7% | +3.1% | +6.8% |
| May 30, 2014 | 5 selling | −1.6% | −9.2% | +3.7% |
| May 31, 2013 | 5 selling | −4.6% | −9.1% | −17.8% |
| May 31, 2012 | 3 selling | −2.1% | −7.7% | −7.3% |